2013
DOI: 10.6004/jnccn.2013.0083
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Early-Stage Esophageal Adenocarcinoma

Abstract: Although T2,N0,M0 esophageal adenocarcinoma is grouped with other locoregional disease by NCCN, no consensus exists about how it should be treated. One of the inherent complexities of treating T2,N0,M0 esophageal adenocarcinoma is the inaccuracy of the clinical staging. In addition, conflicting evidence exists about whether neoadjuvant therapy adds any benefit to esophagectomy. A 52-year-old patient recently seen at the Robert H. Lurie Comprehensive Cancer Center illustrates the complexity of these issues. (JN… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…However, such studies have produced mixed results. For example, some studies have suggested that cancer survivors may be more likely to change their health behaviors than the general population [ 5 , 6 ], whereas others have provided opposite findings [ 7 9 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, such studies have produced mixed results. For example, some studies have suggested that cancer survivors may be more likely to change their health behaviors than the general population [ 5 , 6 ], whereas others have provided opposite findings [ 7 9 ].…”
Section: Introductionmentioning
confidence: 99%